What we doState-of-the-art biotechnology
centered on antibody engineering
Areas of focus
Kyowa Kirin is a Japan-based Global Specialty Pharmaceutical Company, contributing to
human health and well-being worldwide through innovative drug discovery and
global commercialization, driven by state-of-the-art antibody technologies,
in the core therapeutic areas of oncology, nephrology,
central nervous system and immunology.
centered on antibody
Technology-driven drug discovery
The novel drug discovery of Kyowa Kirin is firmly
supported by the exquisite experience and
technologies in research, development and
manufacture of biologics, and by open
This unique style of drug discovery is
what we call technology-driven drug discovery,
on 4 key modalities below.
ESPO® / NESP®
NESP® is an erythropoiesis stimulating agent (ESA) with longer-lasting effect than conventional erythropoietin drugs. It is effective for improving renal anemia with reduced administration frequency.
REGPARA® is a new class of agent for the treatment of secondary hyperparathyroidism. REGPARA® acts on parathyroid calcium receptor directly and suppresses parathyroid hormone secretion, while simultaneously lowering serum calcium and phosphorus levels.
GRAN® / Peglasta® / Neulasta®
GRAN® (Filgrastim) is a human colony-stimulating factor (G-CSF) produced by genetic recombination technology. It works to selectively increase the count of a type of white blood cell called neurotrophil, as well as increase their functional efficacy.
Romiplate®/ Nplate®, a genetically recombinant protein, stimulates platelet production via stimulation of the thrombopoietin receptors.
Crysvita® is a recombinant fully human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23 (FGF23). By blocking excess FGF23 in patients, Crysvita® is intended to increase phosphate reabsorption in the kidney and increase the production of vitamin D, which enhances intestinal absorption of phosphate and calcium in patients with X linked hypophosphatemia.
POTELIGEO® (mogamulizumab-kpkc) is a humanized monoclonal antibody that targets CC chemokine receptor 4 (CCR4), which is frequently expressed on leukemic cells of certain hematologic malignancies including cutaneous T-cell lymphomas (CTCL), such as mycosis fungoides and Sézary syndrome.
Numerous promising pharmaceutical
candidates are emerging from our
pipelines the result of our
never-ending efforts to hone the edge of our
innovation in medical care.
Around the world
Seamless collaboration between regions
delivery of novel medicines
to patients around the world,
close ties to research partners.
We are open and flexible to strategic collaborations
with pharmaceuticals, biotech,
and academia partners.